343 related articles for article (PubMed ID: 36552895)
1. PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity.
Alannan M; Seidah NG; Merched AJ
Cells; 2022 Dec; 11(24):. PubMed ID: 36552895
[TBL] [Abstract][Full Text] [Related]
2. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
Lu X
Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
[TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
4. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
[TBL] [Abstract][Full Text] [Related]
7. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N
Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367
[TBL] [Abstract][Full Text] [Related]
8. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
9. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
[TBL] [Abstract][Full Text] [Related]
12. Role of PCSK9 in lipid metabolism and atherosclerosis.
Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
[TBL] [Abstract][Full Text] [Related]
13. A promising therapy for fatty liver disease: PCSK9 inhibitors.
Han L; Wu L; Yin Q; Li L; Zheng X; Du S; Huang X; Bai L; Wang Y; Bian Y
Phytomedicine; 2024 Jun; 128():155505. PubMed ID: 38547616
[TBL] [Abstract][Full Text] [Related]
14. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
15. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
16. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 and cancer: Rethinking the link.
Mahboobnia K; Pirro M; Marini E; Grignani F; Bezsonov EE; Jamialahmadi T; Sahebkar A
Biomed Pharmacother; 2021 Aug; 140():111758. PubMed ID: 34058443
[TBL] [Abstract][Full Text] [Related]
18. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
Kockx M; Glaros E; Leung B; Ng TW; Berbée JF; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PC; Meikle PJ; Kritharides L
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1338-49. PubMed ID: 27150391
[TBL] [Abstract][Full Text] [Related]
19. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk W; Le May C; Cariou B
Trends Endocrinol Metab; 2018 Jun; 29(6):420-434. PubMed ID: 29665987
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.
Pirro M; Bianconi V; Francisci D; Schiaroli E; Bagaglia F; Sahebkar A; Baldelli F
J Cell Mol Med; 2017 Dec; 21(12):3150-3161. PubMed ID: 28722331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
